The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

NCT Number	NCT07612878
Lead Sponsor	Sanofi
Conditions	COPD (Chronic Obstructive Pulmonary Disease)
Enrollment	350 participants
Start Date	2026-07-31
Primary Completion	2029-06-30 (estimated)
Study Completion	2029-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02